Format

Send to

Choose Destination
Cancer Biol Ther. 2016 Aug 12:1-5. [Epub ahead of print]

Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site.

Author information

1
a Medical Oncology Unit A.O. Papardo & Department of Human Pathology University of Messina , Italy.
2
b Pathology Unit , Istituto Nazionale Tumori "Fondazione G. Pascale"-IRCCS , Naples , Italy.
3
c Nuclear Medicine Unit , A.O. Papardo , Messina , Italy.
4
d Cell Biology and Biotherapy Unit , Istituto Nazionale Tumori "Fondazione G. Pascale"-IRCCS , Naples , Italy.

Abstract

During the last decade the therapeutic landscape of Non Small Cell Lung Cancer (NSCLC) has profoundly changed with the identification of actionable genetic alterations that defined molecularly selected subgroups of patients with specific clinic-pathological characteristics and increased sensitivity to specific targeted agents. The presence of ROS1 rearrangements defines a small subgroup of lung adenocarcinomas (∼1-2%) with peculiar clinic-pathological characteristics and increased sensitivity to Crizotinib. It has been reported that ROS1-tranlslocated NSCLCs may also respond well to Pemetrexed-based chemotherapy. Moreover, patients with oncogene-addicted NSCLC may present peculiar pattern of metastatization and, in some instances, are associated with unusual site of metastases. Herein, we present a case of a young woman with bilateral ovarian metastases from a ROS1-positive adenocarcinoma of the lung with a lengthy progression-free survival on Pemetrexed-containing chemotherapy.

KEYWORDS:

NSCLC; ROS1; genetic rearrangements; long survivor; ovarian metastases; pemetrexed

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center